New PTH test could Fine-Tune mineral balance in kidney dialysis

NCT ID NCT02859220

Completed Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new method of measuring parathyroid hormone (PTH) can help doctors better manage calcium and phosphate levels in people on hemodialysis. About 80 patients with end-stage kidney disease will be randomly assigned to have their PTH measured either with the standard test or with a newer test that distinguishes between active and inactive PTH fragments. The goal is to see if the new test helps patients more easily meet international targets for calcium, phosphorus, and related minerals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PTH 1-84 Complete (CAP) and ratio PTH 1-84/7-84 measurement
What this could lead to: If successful, this could improve how doctors adjust treatment for calcium and phosphate imbalances in dialysis patients, helping them meet health targets more easily.
What could go wrong: This is a small, early-stage study focused on testing a measurement method, not a treatment. The new test may not lead to better patient outcomes or may be too complex for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS PATIENTS

Contacts and locations

Locations

CHU de Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.